MCID: VLV011
MIFTS: 49

Vulvovaginal Candidiasis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Vulvovaginal Candidiasis

MalaCards integrated aliases for Vulvovaginal Candidiasis:

Name: Vulvovaginal Candidiasis 12 3 15 17
Candidiasis of Vulva and Vagina 12 32
Candidiasis, Vulvovaginal 43 71
Candidiasis Vulvovaginal 54
Candidal Vulvovaginitis 12
Monilial Vulvovaginitis 12
Candidal: Cervix 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2272
ICD9CM 34 112.1
MeSH 43 D002181
NCIt 49 C2914
SNOMED-CT 67 72605008
ICD10 32 B37.3
UMLS 71 C0700345

Summaries for Vulvovaginal Candidiasis

CDC : 3 Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Other names for this infection are "vaginal candidiasis," "vulvovaginal candidiasis," or "candidal vaginitis."

MalaCards based summary : Vulvovaginal Candidiasis, also known as candidiasis of vulva and vagina, is related to vaginitis and vulvar vestibulitis syndrome. An important gene associated with Vulvovaginal Candidiasis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A candidiasis that involves fungal infection of the vaginal mucous membranes in women caused by Candida albicans. The symptoms include intense vulval pruritus, burning, erythema and dyspareunia associated with a creamy white, curd-like discharge.

Wikipedia : 74 Vaginal yeast infection, also known as candidal vulvovaginitis and vaginal thrush, is excessive growth... more...

Related Diseases for Vulvovaginal Candidiasis

Diseases related to Vulvovaginal Candidiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 vaginitis 31.2 TLR2 LAP3 DEFB4A CCR6
2 vulvar vestibulitis syndrome 30.8 NLRP3 MBL2 IL1RN
3 amyotrophic lateral sclerosis 3 30.6 SKAP2 CLEC7A CCR6
4 cervicitis 30.5 TLR2 IL2 DEFB4A
5 bacterial vaginosis 30.5 TLR2 MBL2 LAP3 IL4 IL1RN DEFB4A
6 urethritis 30.3 TLR2 DEFB4A DEFA5
7 immunoglobulin alpha deficiency 30.2 MBL2 CD79A CCR6
8 acquired immunodeficiency syndrome 29.8 IL2 IFNA1 CD79A CCR6
9 candidiasis 29.7 TLR2 SKAP2 MBL2 IL4 IL2 DEFB4A
10 anogenital venereal wart 29.6 TLR2 IL2 IFNA1 CCR6
11 tinea pedis 29.4 DEFB4A CLEC7A CLEC6A CARD9
12 skin disease 29.3 TLR2 IL4 IL2 DEFB4A CD79A CCR6
13 exanthem 29.2 NLRP3 IL2 IL1RN IFNA1 CCR6
14 immune deficiency disease 29.2 TLR2 MBL2 IL4 IL2 IFNA1 CD79A
15 cutaneous candidiasis 29.0 CLEC7A CLEC6A CCR6 CARD9
16 bacterial infectious disease 28.8 TLR2 MBL2 LCN2 IL1RN DEFB4A DEFB1
17 dermatophytosis 28.7 DEFB4A CLEC7A CLEC6A CCR6 CARD9
18 oral candidiasis 28.3 SKAP2 IL1RN DEFB4A DEFB1 CLEC7A CLEC6A
19 vaginal disease 28.2 TLR2 IL2 IFNA1 DEFB4A CLEC7A CCR6
20 chronic mucocutaneous candidiasis 27.9 TLR2 IL4 IFNA1 CLEC7A CLEC6A CCR6
21 vulvovaginitis 10.9
22 candida glabrata 10.8
23 vaginal discharge 10.8
24 immunoglobulin g deficiency 10.6 MBL2 CD79A
25 prosthetic joint infection 10.5 TLR2 MBL2
26 mycobacterium kansasii 10.5 TLR2 NLRP3
27 fungal keratitis 10.5 TLR2 CLEC7A
28 haemophilus influenzae 10.5 TLR2 CLEC7A
29 acute pericementitis 10.5 TLR2 DEFB4A
30 trichomoniasis 10.5
31 overgrowth syndrome 10.5
32 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.4 IL4 IL2
33 cryptosporidiosis 10.4 MBL2 DEFB4A CD79A
34 denture stomatitis 10.4 SKAP2 DEFB4A CLEC7A
35 mycobacterium abscessus 10.4 TLR2 NLRP3 CLEC7A
36 virus associated hemophagocytic syndrome 10.4 IL4 IL2
37 cryopyrin-associated periodic syndrome 10.4 NLRP3 IL1RN
38 trichomonas vaginalis trichomoniasis 10.4
39 jak3-deficient severe combined immunodeficiency 10.4 IL4 IL2
40 amebiasis 10.3 TLR2 IL4 CD79A
41 chronic graft versus host disease 10.3 LCN2 CD79A
42 ige responsiveness, atopic 10.3
43 neisseria meningitidis infection 10.3 TLR2 MBL2 IL1RN
44 atopic keratoconjunctivitis 10.3 IL4 IL2
45 rheumatic heart disease 10.3 TLR2 MBL2 IL4
46 rheumatic fever 10.3 TLR2 MBL2 IL2
47 selective igg deficiency disease 10.3 MBL2 CD79A
48 microscopic colitis 10.3 IL4 IL2 CD79A
49 conjunctivitis 10.3 NLRP3 IL4 IL2
50 extrapulmonary tuberculosis 10.3 TLR2 MBL2 IL1RN

Comorbidity relations with Vulvovaginal Candidiasis via Phenotypic Disease Network (PDN): (show all 12)


Acute Cystitis Anxiety
Bronchitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hypertension, Essential
Hypothyroidism Oral Candidiasis
Osteoporosis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Vulvovaginal Candidiasis:



Diseases related to Vulvovaginal Candidiasis

Symptoms & Phenotypes for Vulvovaginal Candidiasis

MGI Mouse Phenotypes related to Vulvovaginal Candidiasis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CARD9 CCR6 CD79A CLEC6A CLEC7A GGT1
2 immune system MP:0005387 9.83 CARD9 CCR6 CD79A CLEC6A CLEC7A GGT1
3 renal/urinary system MP:0005367 9.23 CD79A CLEC6A GGT1 IL4 LCN2 MBL2

Drugs & Therapeutics for Vulvovaginal Candidiasis

Drugs for Vulvovaginal Candidiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Dequalinium Approved, Investigational Phase 4 6707-58-0
6
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
7 Cytochrome P-450 Enzyme Inhibitors Phase 4
8 Hormone Antagonists Phase 4
9 Antifungal Agents Phase 4
10
Metronidazole Approved Phase 3 443-48-1 4173
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
12
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
13
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
14
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
15
Secnidazole Approved Phase 3 3366-95-8
16 Anti-Infective Agents, Local Phase 3
17 Cytochrome P-450 CYP3A Inhibitors Phase 3
18 Antiprotozoal Agents Phase 3
19 Antiparasitic Agents Phase 3
20 Anti-Bacterial Agents Phase 3
21 Amebicides Phase 3
22 Liposomal amphotericin B Phase 3
23 Clindamycin phosphate Phase 3
24 Clindamycin palmitate Phase 3
25 Alkylating Agents Phase 3
26
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
27
Titanium dioxide Approved Phase 2 13463-67-7
28
Metformin Approved Phase 2 657-24-9 14219 4091
29
Canagliflozin Approved Phase 2 842133-18-0
30 Vaccines Phase 1, Phase 2
31 Rezafungin Phase 2
32 Sodium-Glucose Transporter 2 Inhibitors Phase 2
33 HIV Protease Inhibitors Phase 2
34
protease inhibitors Phase 2
35 Sitagliptin Phosphate Phase 2
36 Hypoglycemic Agents Phase 2
37 Dipeptidyl-Peptidase IV Inhibitors Phase 2
38 Incretins Phase 2
39 Anti-Obesity Agents Phase 2
40 Anti-Infective Agents Phase 2
41 Acidophilus Phase 1
42
Butoconazole Approved 64872-77-1, 64872-76-0 47472
43
Terconazole Approved Early Phase 1 67915-31-5 441383
44
Iron Approved, Experimental 15438-31-0, 7439-89-6 27284 23925
45
Itraconazole Approved, Investigational 84625-61-6 55283
46 Trace Elements
47
Hydroxyitraconazole
48 Nutrients
49 Micronutrients
50 Bifidobacterium

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis. Completed NCT02248506 Phase 4
2 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
3 Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
4 An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
5 A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
6 Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE Completed NCT00194324 Phase 4 Miconazole nitrate
7 A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis Completed NCT00000951 Phase 4 Fluconazole
8 Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis Unknown status NCT03473418 Phase 3 Ketoconazole;Terconazole
9 Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories. Completed NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
10 Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management Completed NCT00353561 Phase 3 Boric;Fluconazole
11 A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis. Completed NCT01806623 Phase 3 Fluconazole
12 An Investigator-blinded, Active-controlled Phase 3 Study to Prove the Non-inferior Efficacy of a Clotrimazole Ovule (500 mg) Versus a Clotrimazole Vaginal Tablet (500 mg) in Vaginal Candidiasis Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
13 A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001 Completed NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
14 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo. Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
15 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03734991 Phase 3 Ibrexafungerp;Placebo
16 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
17 Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia. Completed NCT02111629 Phase 3 Fluconazole and Secnidazole
18 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
19 A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules Versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects With Recurrent Vulvovaginal Candidiasis Recruiting NCT03840616 Phase 3 VT-1161 150 mg capsule;Fluconazole 150 mg
20 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Recruiting NCT04029116 Phase 3 Fluconazole Tablet;IBREXAFUNGERP;Placebo oral tablet
21 Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) Recruiting NCT03059992 Phase 3 Ibrexafungerp
22 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Active, not recruiting NCT03562156 Phase 3 VT-1161;Placebo
23 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis Active, not recruiting NCT03561701 Phase 3 VT-1161;Placebo
24 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC). Active, not recruiting NCT03987620 Phase 3 Ibrexafungerp;Placebo
25 Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC) Withdrawn NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
26 Multi-center, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study to Compare the Therapeutic Efficacy, Safety, and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate Pessaries in the Treatment of VVC Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
27 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis Completed NCT02267382 Phase 2 VT-1161;Placebo
28 A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis Completed NCT01891331 Phase 2 VT-1161;Fluconazole
29 A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
30 A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Fluconazole Versus Fluconazole And MGCD290 for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
31 A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Completed NCT03253094 Phase 2 Fluconazole;SCY-078
32 Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
33 A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
34 A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
35 A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC) Completed NCT02866227 Phase 2 TOL-463;TOL-463
36 A Double-Blind, Randomized Trial of Monthly Treatment With Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories Versus Placebo for Preventing Vaginal Infections in HIV-seronegative Women Completed NCT01230814 Phase 2 Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate);Placebo
37 A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference Arm Completed NCT00642278 Phase 2 Canagliflozin (JNJ-28431754);Sitagliptin;Placebo
38 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects Completed NCT00650806 Phase 2 Canagliflozin (JNJ-28431754);Placebo
39 Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis Recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
40 A Randomized, Double-Blind, Placebo-Controlled Trial Of TOL-463 Insert for Suppression Of Bacterial Vaginosis (BV) [SUBVert] Recruiting NCT03930745 Phase 2 TOL-463
41 A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Withdrawn NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
42 A Double-Blind,Randomized Placebo-Controlled Study Using Probiotic Lactobacillus GR-1 and RC-14 as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
43 A Phase I Randomized Placebo Controlled Study of a Virosome Formulated Anti-Candida Vaccine (PEV7) Administered by the Vaginal (PEV7C) or Intramuscular (PEV7B) Route to Healthy Adult Volunteers Completed NCT01067131 Phase 1
44 Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women. Completed NCT02730494 Phase 1
45 A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis Completed NCT01812889 Phase 1 TOL-463 Vaginal ovule;TOL-463 Vaginal gel
46 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Unknown status NCT03075046
47 "A Comparison Study of the WaterWorks® Douching Device vs. Commercial OTC Douching Device for the Reduction or Abatement of Perceived Vaginal Odor With or Without Complaints of Discharge in Women With no Infectious Causes of Vaginitis" Unknown status NCT00417365
48 Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis Unknown status NCT02185456 Early Phase 1 750 mg metronidazole/ 200 mg miconazole vaginal suppository;Standard of care
49 A Randomized Study Evaluating the Therapeutic Equivalence and Safety of Butoconazole Nitrate Vaginal Cream, 2% and Gynazole 1 (Butoconazole Nitrate) Vaginal Cream, 2%, Against a Vehicle Control in the Treatment of Vulvovaginal Candidiasis Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
50 A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis Completed NCT02888197

Search NIH Clinical Center for Vulvovaginal Candidiasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


butoconazole
Butoconazole nitrate
Clotrimazole
Fluconazole
Gentian Violet
Itraconazole
Ketoconazole
Miconazole
Miconazole Nitrate
MICONAZOLE NITRATE PWDR
NYSTATIN PWDR
terconazole
tioconazole

Cochrane evidence based reviews: candidiasis, vulvovaginal

Genetic Tests for Vulvovaginal Candidiasis

Anatomical Context for Vulvovaginal Candidiasis

MalaCards organs/tissues related to Vulvovaginal Candidiasis:

40
Testes, Skin, Cervix, Colon, Neutrophil, T Cells, B Cells

Publications for Vulvovaginal Candidiasis

Articles related to Vulvovaginal Candidiasis:

(show top 50) (show all 1170)
# Title Authors PMID Year
1
Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. 61 54
19910100 2010
2
Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. 54 61
18715406 2008
3
MBL2 genetic screening in patients with recurrent vaginal infections. 61 54
18211540 2008
4
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 54 61
17470593 2007
5
Mannose-binding lectin and vulvovaginal candidiasis. 54 61
16256117 2006
6
Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. 61 54
15825027 2005
7
Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. 54 61
12942410 2003
8
Investigating the expression of ALS2 and ALS9 genes along with allele frequency of ALS9 in patients with vulvovaginal candidiasis. 61
32084624 2020
9
A therapeutic effect of Nigella sativa extract on female Wistar rats vulvovaginal candidiasis model. 61
32153156 2020
10
Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion. 61
32552788 2020
11
Recent Advances on Vaginal delivery for the Treatment of Vulvovaginal candidiasis. 61
32564767 2020
12
[Epidemiology and etiology of vulvovaginal candidiasis in Spanish and immigrants' women in Fuenlabrada (Madrid)]. 61
32304363 2020
13
Recurrent vulvovaginal candidiasis. 61
32513647 2020
14
Current burden of serious fungal infections in Republic of Congo. 61
32181941 2020
15
Association of sexual function and psychological symptoms including depression, anxiety and stress in women with recurrent vulvovaginal candidiasis 61
31640303 2020
16
Activities of Nerol, a natural plant active ingredient, against Candida albicans in vitro and in vivo. 61
32248438 2020
17
The Role of 17β-Estrogen in Candida albicans Adhesion on Human Vaginal Epithelial Cells via FAK Phosphorylation. 61
32185617 2020
18
Vulvar pain: The revealing scenario of leading comorbidities in 1183 cases. 61
32563924 2020
19
Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. 61
32434758 2020
20
Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. 61
32375724 2020
21
Diagnosis and Treatment of Vaginal Discharge Syndromes in Community Practice Settings. 61
32350529 2020
22
Effect of progesterone on Candida albicans biofilm formation under acidic conditions: A transcriptomic analysis. 61
32173268 2020
23
Hormones modulate Candida vaginal isolates biofilm formation and decrease their susceptibility to azoles and hydrogen peroxide. 61
31254346 2020
24
Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis. 61
32393342 2020
25
Copper IUD increases virulence of non-albicans Candida species isolated from women with vulvovaginal candidiasis. 61
31990231 2020
26
Probiotics to Augment Antifungal Treatment of Vulvovaginal Candidiasis. 61
32227830 2020
27
Soluble beta-glucan salecan improves vaginal infection of Candida albicans in mice. 61
31982527 2020
28
Candida africana vulvovaginitis: Prevalence and geographical distribution. 61
32317216 2020
29
Prepubertal and Adolescent Vulvovaginitis: What to Do When a Girl Reports Vaginal Discharge. 61
32275761 2020
30
The Interleukin (IL) 17R/IL-22R Signaling Axis Is Dispensable for Vulvovaginal Candidiasis Regardless of Estrogen Status. 61
31805183 2020
31
Data on statistical experimental design to formulate amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis. 61
32211458 2020
32
[Analysis of homology and drug sensitivity of vaginal isolates of 10 patients with recurrent vulvovaginal candidiasis in recurrent episodes]. 61
32268715 2020
33
Sunlight exposure, consumption of vitamin D-rich foods and vulvovaginal candidiasis in an African population: a prevalence case-control study. 61
31636409 2020
34
Low prevalence of antifungal resistant Candida africana, in the C. albicans complex causing vulvovaginal candidiasis. 61
32215332 2020
35
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis. 61
31812702 2020
36
Amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis. 61
31887870 2020
37
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. 61
32106438 2020
38
Noncandidal vaginitis: a comprehensive approach to diagnosis and management. 61
31513780 2020
39
Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis. 61
31705810 2020
40
Garlic alters the expression of putative virulence factor genes SIR2 and ECE1 in vulvovaginal C. albicans isolates. 61
32107396 2020
41
Syngonanthus nitens (Bong.) Ruhland Derivatives Loaded into a Lipid Nanoemulsion for Enhanced Antifungal Activity Against Candida parapsilosis. 61
32183660 2020
42
In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis. 61
31901238 2020
43
Association between Vaginal Infections and the Types and Viral Loads of Human Papillomavirus: A Clinical Study Based on 4,449 Cases of Gynecologic Outpatients. 61
32273935 2020
44
Antifungal and Antivirulence Activities of Hydroalcoholic Extract and Fractions of Platonia insignis Leaves against Vaginal Isolates of Candida Species. 61
32013047 2020
45
Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. 61
32373104 2020
46
Formulation and technology development of vaginal pessaries with probiotic activity. 61
32545988 2020
47
Diagnostic performance of two molecular assays for the detection of vaginitis in symptomatic women. 61
31502121 2020
48
Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. 61
31299136 2020
49
Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of Candida krusei. 61
32508766 2020
50
[Effect of butyl alcohol extract of Baitouweng Decoction on vaginal mucosal neutrophil chemotaxis in vulvovaginal candidiasis mice]. 61
32237319 2020

Variations for Vulvovaginal Candidiasis

Expression for Vulvovaginal Candidiasis

Search GEO for disease gene expression data for Vulvovaginal Candidiasis.

Pathways for Vulvovaginal Candidiasis

Pathways related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 TLR2 NLRP3 MBL2 LCN2 IL4 IL2
2
Show member pathways
12.47 TLR2 NLRP3 IL1RN IFNA1 CARD9
3
Show member pathways
12.09 TLR2 LCN2 IL4 DEFB4A
4 12.01 TLR2 IL4 IL2 IL1RN IFNA1 CD79A
5 11.98 NLRP3 IFNA1 DEFB4A DEFA5 CARD9
6
Show member pathways
11.97 TLR2 LCN2 DEFB4A DEFB1 DEFA5 CCR6
7 11.96 TLR2 IFNA1 CLEC7A CARD9
8
Show member pathways
11.89 NLRP3 IL2 CLEC7A CLEC6A CARD9
9 11.65 MBL2 DEFB4A DEFB1 DEFA5
10 11.56 IL4 IL2 CCR6

GO Terms for Vulvovaginal Candidiasis

Cellular components related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 NLRP3 MBL2 LCN2 IL4 IL2 IL1RN
2 extracellular space GO:0005615 9.32 MBL2 LCN2 IL4 IL2 IL1RN IFNA1

Biological processes related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.88 LCN2 IL4 IL2 IL1RN IFNA1
2 defense response to bacterium GO:0042742 9.83 MBL2 LCN2 DEFB4A DEFB1 DEFA5
3 immune system process GO:0002376 9.81 TLR2 NLRP3 MBL2 LCN2 IL2 CLEC7A
4 immune response GO:0006955 9.8 TLR2 IL4 IL2 IL1RN DEFB4A DEFB1
5 defense response to Gram-negative bacterium GO:0050829 9.78 DEFB4A DEFB1 DEFA5
6 B cell differentiation GO:0030183 9.77 IL4 IFNA1 CD79A
7 defense response GO:0006952 9.77 NLRP3 IFNA1 DEFB4A DEFB1 DEFA5
8 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.73 DEFB4A DEFB1 DEFA5
9 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.71 NLRP3 CLEC7A CARD9
10 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.69 LCN2 IL4 IL2
11 B cell activation GO:0042113 9.63 SKAP2 IL4 CD79A
12 antimicrobial humoral response GO:0019730 9.62 LCN2 DEFB4A DEFB1 DEFA5
13 innate immune response GO:0045087 9.61 TLR2 NLRP3 MBL2 LCN2 DEFB1 DEFA5
14 killing by host of symbiont cells GO:0051873 9.59 MBL2 DEFA5
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.58 IL4 IL2
16 negative regulation of T-helper 17 cell differentiation GO:2000320 9.58 IL4 IL2
17 innate immune response in mucosa GO:0002227 9.58 IL4 DEFB1 DEFA5
18 positive regulation of interleukin-13 production GO:0032736 9.57 NLRP3 IL4
19 negative regulation of acute inflammatory response GO:0002674 9.55 NLRP3 IL4
20 cytokine secretion involved in immune response GO:0002374 9.52 TLR2 NLRP3
21 positive regulation of flagellated sperm motility involved in capacitation GO:0060474 9.49 DEFB1 CCR6
22 defense response to Gram-positive bacterium GO:0050830 9.17 TLR2 NLRP3 MBL2 DEFB4A DEFB1 DEFA5

Molecular functions related to Vulvovaginal Candidiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 IL4 IL2 IL1RN IFNA1
2 pattern recognition receptor activity GO:0038187 9.26 TLR2 CLEC7A
3 CCR6 chemokine receptor binding GO:0031731 8.96 DEFB4A DEFB1
4 carbohydrate binding GO:0030246 8.92 MBL2 IL2 CLEC7A CLEC6A

Sources for Vulvovaginal Candidiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....